Agios Pharmaceuticals, Inc. (AGIO) Earnings Call Transcript & Summary
April 29, 2026
Earnings Call Speaker Segments
Morgan Sanford
executiveThanks, operator. Hello, everyone, and good morning. We appreciate you being here as we go over Agios Pharmaceuticals' results for the first quarter of 2026 along with our business highlights. The slides accompanying today's call can be found in the Investors area of our site, agios.com. I want to remind you that forward-looking statements will be part of what we say today. Due to a range of risks, uncertainties, and other factors — among them those described in our latest SEC filings and any subsequent submissions we might file — actual outcomes and events may end up differing materially from anything such statements express or imply. Joining me on this call from Agios are Brian Goff, our Chief Executive Officer; Cecilia Jones, our Chief Financial Officer; Tsveta Milanova, our Chief Commercial Officer; and Dr. Sarah Gheuens, our Chief Medical Officer and Head of Research and Development. Once our prepared remarks are finished, we'll take your questions. With that said, I'm happy to hand things over to Brian.
Brian Goff
executiveThanks, Morgan. Morning, everyone, and I appreciate you all being with us today. Could we move to the next slide? At the beginning of this year, we laid out the strategic priorities for 2026, built to fuel near-term execution as well as long-term value creation, and we've gotten off to a solid start, heading into yet another catalyst-rich year with clear momentum behind those priorities. Now to the first quarter highlights on the following slide: net revenues came in at $20.7 million, which works out to 138% growth compared with a year ago. During the first quarter, AQVESME launched commercially in the U.S. for thalassemia, with the REMS fully up and running as of the close of January. We're seeing strong demand right out of the gate. Our outlook hasn't changed: operating expenses for 2026 should come in about level with 2025. We ended the quarter in a solid financial position, with over $1 billion across cash, cash equivalents and marketable securities. On top of that, two things that matter a great deal to our growth inflection have made progress. To start, the U.S. commercial rollout of AQVESME for thalassemia is off to a strong start — as of March 31st, REMS-certified physicians had written 242 prescriptions, which is a big jump from the 44 prescriptions we reported at the end of January. That early momentum reflects solid execution as the launch continues to expand. Tsveta is going to walk through additional details in a moment, yet what we're already seeing demonstrates the impressive execution and rare disease know-how that the Agios commercial organization brings. Turning to my second point: following the pre-sNDA discussion we held with the FDA in Q1, our plan now is to file an sNDA for mitapivat in sickle cell disease during Q2, using the U.S. accelerated approval route — a meaningful move as we work to grow our PK activation franchise into a considerably bigger indication. I'd also like to call out how strong our people are; their ability to react quickly and with rigor to feedback from the FDA speaks to the substantial regulatory and scientific depth we've assembled here at Agios. Let's go to the next slide. If you zoom out, what we're trying to do is create a rare disease business that can last, with rare hematology as the base it stands on. Right now, the work in front of us is getting the U.S. commercial rollout of AQVESME in thalassemia done and moving the mitapivat sNDA submission forward in sickle cell disease. At the same time, we're getting ready for key catalysts a bit further out, and those include Phase II top line results for tebapivat — our more potent, next-generation PK activator — in both lower-risk MDS and sickle cell disease, coming this year. Looking even further ahead, we keep pushing our earlier-stage clinical efforts forward and we're choosy about where we might expand into additional rare hematology diseases, all in service of lasting growth. Okay, let's move on to the following slide, and I'll hand things over to Cecilia for the financial discussion. Cecilia?
Cecilia Jones
executiveThanks, Brian. On the slide that follows, you'll see a recap of our financial performance for the first quarter. As we've noted before, mitapivat net revenues will be broken out into U.S. and ex-U.S. pieces. During Q1, worldwide mitapivat net revenues came to $20.7 million, of which $18.8 million came from U.S. sales, fueled by the recent AQVESME launch in thalassemia. Sales outside the U.S. totaled $1.9 million, which mirrors the quarterly swings we had anticipated. R&D expense for the first quarter was $81 million, up about $8 million versus the prior year, reflecting workforce-related costs tied to pipeline advancement efforts along with higher mitapivat process development expenses. SG&A spend came in at $48 million, roughly $7 million above the prior year, driven by more activity supporting the U.S. commercial launch of AQVESME in thalassemia and higher stock compensation expense. We closed the quarter holding more than $1 billion in cash, cash equivalents and marketable securities, which puts us in a strong position to stay disciplined as we invest to maximize portfolio value and build a pipeline for long-term growth. Moving to the next slide on our capital allocation approach, our priorities haven't changed. First, we'll keep maximizing the U.S. commercial launch of AQVESME in thalassemia. Second, we're managing operating expenses in a manner consistent with our long-term value creation. Given our current plans and accounting for the mitapivat confirmatory clinical trial in sickle cell disease, we expect 2026 operating expenses to be roughly flat versus 2025. Lastly, we'll keep diversifying our pipeline, drawing on both internal capabilities and external innovation as we carry out our 2026 priorities with a disciplined approach to long-term growth. Please move ahead to the next slide, and I'll hand things to Tsveta to walk through commercial highlights and the early launch dynamics for AQVESME's use in thalassemia.
Tsveta Milanova
executiveThanks, Cecilia. Could we go to the following slide? The way our commercial side performed during Q1 shows truly outstanding execution while we shifted where our field force puts its attention — moving away from PK deficiency and toward thalassemia. Within the United States, net revenues came to $18.8 million, which strong early demand for the AQVESME launch drove. Beyond the United States, we recorded $1.9 million in net revenue, mostly driven by thalassemia use in the GCC. That matches what we anticipated, considering the early market access situation before government procurement is secured. Just like in earlier quarters, we anticipate ongoing fluctuation from one quarter to another, caused by ordering patterns, inventory dynamics and gross to net. Kindly advance to the slide after this one. What we have observed from the AQVESME U.S. launch up to now makes me quite optimistic, and I want to begin by recognizing the enormous efforts of our commercial, medical and patient support teams. Executing a launch in rare diseases is complicated, and the early strides we are witnessing speak to both solid preparation and the deep rare disease commercialization know-how we have developed at Agios, backed by tight coordination throughout the organization. During the first quarter, REMS-certified physicians wrote 242 prescriptions, which stands as a significant early signal of robust demand, though we should remember that the REMS went live in late January. Let me offer a few points worth calling out that help explain how we view these early signals. When we finished the first quarter, early uptake had clustered among highly engaged patients, including transfusion-dependent as well as motivated non-transfusion-dependent patients; that aligns with the early launch dynamics one would expect. During the first quarter, the gap between prescription and initiation came in shorter than we had anticipated. That happened because patients engaged early with greater motivation to begin treatment, physicians were ready to prescribe, and REMS coordination worked effectively; even so, we still anticipate typical initiation timelines of roughly 10 to 12 weeks over the next several quarters as we move further into patient segments whose clinical engagement is less frequent. The geographic reach of early prescriber uptake has been encouraging, and community-based hematologist oncologists have propelled it. What we have seen thus far gives us confidence in how ready we are to launch and in the quality of demand during these opening days of launch; even so, at this early point in the launch we do not interpret early prescription volumes as becoming a steady run rate, especially as demand shifts further toward non-transfusion-dependent patients and uptake extends past the most motivated, highly engaged patients. On the next slide, you can see both how strongly AQVESME has been received early on and how we are building toward sustainable growth. Feedback coming from the field has been highly encouraging. Physicians and patients acknowledge AQVESME's meaningful clinical profile. REMS onboarding is proceeding without friction, and our patient support services are assisting patients in starting therapy. Looking forward, three priorities guide us: first, widening prescriber engagement in academic as well as community settings; second, extending adoption to non-transfusion-dependent patients, who make up most adult diagnoses; and third, pushing payer access forward to enable timely treatment initiation. All things considered, the way AQVESME has been embraced during these initial launch days gives us reason for optimism, and our attention remains on carrying out the critical initiatives that will support lasting uptake as time goes on. The execution the team has shown so far makes me extremely proud. Results from the first quarter underscore both how prepared the team was for this launch and its thorough grasp of this marketplace. In our view, this solid base puts us in position to fulfill our goals for the U.S. launch of AQVESME, along with possible upcoming launches as we pursue growth of our rare disease portfolio. Kindly advance to the following slide; and having said that, I'll now pass the call to Sarah, who will walk through the quarter's key R&D highlights.
Sarah Gheuens
executiveThank you, Tsveta. Let's move on to the following slide, please. Our pipeline remains robust, built upon our PK activation franchise and enhanced by distinctive early-stage clinical programs. In the first quarter, we outlined our intention to launch 2 pediatric trials of mitapivat for thalassemia: ENERGIZE-KidsT, which focuses on patients who are transfusion-dependent, and ENERGIZE-Kids, for those who are non-transfusion-dependent. We are enthusiastic about the prospect of delivering this transformative therapy to pediatric populations. Additionally, we look forward to multiple data readouts in the second quarter, including Phase IIb top line results for tebapivat, our next-generation PK activator being studied in low-risk MDS. That research is evaluating three dosage strengths — 10 milligrams, 15 milligrams, and 20 milligrams — across a wide range of patients, and its main goal is eight weeks in a row without needing a transfusion. We recognize this carries greater risk, but we see real promise for an oral treatment option in this area. Moving on to the following slide. During the first quarter, we wrapped up a pre-sNDA meeting with the FDA, and we came to agreement on a route toward accelerated approval in the United States for mitapivat as a treatment for sickle cell disease. Following that, we've participated in both informal and formal interactions aimed at obtaining official consensus regarding the confirmatory clinical trial that this pathway mandates. The way those talks have gone pleases us, and we now anticipate submitting an sNDA during the second quarter. We're eager to present more findings from the RISE UP Phase III study at a medical congress soon, and that will include the analyses that informed how we selected the primary endpoint for the confirmatory clinical trial. If we take a broader view, when designing that confirmatory trial, our priorities included operational feasibility — things like how long enrollment takes and how quickly the study can be finished — while we also sought to maximize the odds of success and the chance to further strengthen the mitapivat label, should U.S. full approval be granted on the basis of the confirmatory trial's results. Let's go to the next slide. Meanwhile, tebapivat, our next-generation PK activator, is moving forward in Phase II studies spanning low-risk MDS and sickle cell disease. When we created tebapivat, our goal was to move past what first-generation PK activators could do. Its structure sets it apart, delivering strong dual activation of PKR and PKM2, along with PK and PD characteristics that allow for one dose per day and no taper requirement. What's more, the initial clinical results mirror those intended design traits. Among sickle cell disease patients, tebapivat demonstrated an extended half-life of roughly 87 to 93 hours, dose-related decreases in 2,3-DPG and rises in ATP, plus pharmacodynamic responses that remain sustained as long as four weeks following the final dose. At the 5-milligram once-daily dose, we additionally observed an average hemoglobin gain of 1.9 grams per deciliter. Past red blood cell metabolism, tebapivat displays wider biological effects stemming from PKM2 activation. When we looked at preclinical models, we saw antifibrotic activity—things like less glomerular damage and weaker myofibroblast signaling—which suggests this could matter for disease processes beyond just mature red blood cells. In low-risk MDS, we picked up early clinical signals, such as transfusion independence among patients in the low transfusion burden group. That said, drug exposure came in 60% below what we saw in healthy volunteers, so we launched a study at higher doses. We're running a Phase IIb study that uses larger doses in a broader group of lower-risk MDS patients. What we're trying to prove is whether hitting PKR and PKM2 harder can drive biological effects deeper into erythroid maturation inside the bone marrow. At the same time, for sickle cell disease, our Phase II trial is designed to get a fast read on hemoglobin response plus important hemolysis markers, so we can determine whether this deeper biology translates into wider clinical benefit. We can't wait to report topline results from our Phase IIb trial in low-risk MDS sometime in the first six months of this year, followed by topline Phase II findings in sickle cell disease in the back half of 2026; so with that, please move ahead to the following slide, and I'll hand things back over to Brian for his closing thoughts.
Brian Goff
executiveSarah, thanks. Could we bring up the following slide? As has been discussed during today's session, for Agios, 2026 looks like a year of inflection in growth and rich in catalysts, with significant strides occurring in both our commercial operation and our pipeline. During the opening six months of the year, we moved the regulatory process forward for mitapivat in sickle cell disease, and we look forward to Phase IIb top line results for tebapivat in lower-risk MDS, plus Phase I top line results from healthy volunteers for AG-236. When it comes to the latter six months, we expect Phase II top line results for tebapivat in sickle cell disease, in addition to Phase Ib proof of mechanism results for AG-181 in phenylketonuria. And all year long, our attention stays fixed on carrying out the U.S. commercial launch of AQVESME in thalassemia, aiming to establish a robust and lasting commercial basis. Let's go to the next slide. Taking a broader view, we think what sets Agios apart is having both an expanding commercial foundation and a pipeline that is ever more tilted toward high-value opportunities at later stages. As this graphic illustrates, the potential market opportunity in 2030 represented by our present pipeline exceeds $10 billion. Above all, every item discussed today rests on our dedication to the patients we serve — those dealing with serious and frequently underserved rare diseases, who continue to await improved treatment choices. I'd also like to acknowledge and express gratitude to our staff. It is their concentration, know-how and commitment that turn this progress into reality, whether pushing forward essential clinical and regulatory milestones or carrying out a complicated commercial launch with attentiveness and rigor. With that, we're grateful for your ongoing interest in Agios. At this point I'd like to take questions. Operator, please open the line.
Samantha Semenkow
analystNice work on getting AQVESME out ahead of schedule; keeping to that subject, my first inquiry is simply a bit regarding what kind of demand for AQVESME you're observing so far during the second quarter. I'm curious whether there's somewhat of a bolus element in the first quarter coming from those extremely driven patients. Yet when you examine second quarter prescription results, are you noticing a comparable rhythm in those scripts arriving, plus a rise in health care professionals who are REMS-certified? And I have one more question after this.
Brian Goff
executiveCertainly. Thank you, Sam. I'll hand it to Tsveta to weigh in; and naturally, we'll be keeping to the first quarter dynamics, though clearly there's solid momentum that made us glad to share it today. So Tsveta, would you like to jump in?
Tsveta Milanova
executiveYes, definitely. So like I mentioned, we're really thrilled about how the launch has gone so far and what we've accomplished; we noted that as of March 31st, there were 242 prescriptions written by physicians certified through REMS. What's fueling this initial pickup is truly the patients who are deeply engaged and motivated, and that group covers both those who depend on transfusions and the motivated ones who don't. I wouldn't treat Q1 as the rate we'll sustain in the quarters ahead. That said, here's what I can share: we continue to anticipate quite robust demand and adoption as the team keeps performing at a very high level, and the feedback we're getting from patients and physicians alike regarding the AQVESME profile has been extremely, extremely favorable.
Brian Goff
executiveSam, you had something else to ask?
Samantha Semenkow
analystYes, I did. That helped. A few more questions about tebapivat. To start, regarding when the MDS data arrives, is there anything more specific you can tell us about the timing for that data within this quarter? Second, when it comes to sickle cell disease, how are you evaluating the market opportunity for mitapivat, considering data that a competitor recently released? Also, what's your approach to developing mitapivat? Clearly, you're heading toward an accelerated approval filing, yet tebapivat is coming in the second half, and based on those early efficacy signals you described during the prepared remarks, it might be best-in-class. So as things move ahead, how do you see that market taking shape?
Brian Goff
executiveWe'll take these one at a time. Sarah can speak to tebapivat in MDS and, essentially, what timing we anticipate.
Sarah Gheuens
executiveRight, so Sam, the schedule we've called out is the first half of this year. That's what we're holding to. Then as far as sickle cell disease goes, the timeline is the second half of the year, and the teams are coming along really well on those deliverables.
Brian Goff
executiveAfter that, I’ll hand things back to Tsveta for a comment — Sam, we are obviously in a strong position, with mitapivat and all the progress we discussed this morning on our accelerated pathway for sickle cell disease, plus the advantage of tebapivat, the next-generation, more potent PK activator that we’re awaiting Phase II data for. But Tsveta, maybe you could speak to the overall franchise goal we have.
Tsveta Milanova
executiveAbsolutely — we definitely see a major commercial opening in sickle cell disease, covering both mitapivat and tebapivat. As far as mitapivat goes, we view sickle cell disease as one that could accommodate several treatment choices, and assuming we secure a label, we intend to make the most of that commercial opportunity. That confidence stems from the very strong, favorable feedback we've gotten from the KOL community, which reflects how compelling our hemoglobin responder data is. They're out there talking about why an antihemolytic agent is needed — particularly one where hemoglobin responders can show possible gains on other meaningful endpoints, like quality of life and possibly fewer pain crises. So we can't say much more until we actually see the HIBISCUS data, but our starting point is one of strength, given that this would be our third indication on the market. That community knows the product well. We've got more than 1,000 patient years of data plus solid market experience behind us, and we view that as a strong foundation for building out the franchise. As for tebapivat, naturally we still need to see the Phase II data. We also need to watch how the competitive landscape evolves, but our aim is to position that product as best-in-class, and once we have the data, we'll share more.
Alec Stranahan
analystCongratulations on the early launch momentum you've built during this quarter. I have two things to ask — one about sickle cell, the other about the thal launch. First, regarding thal: for patients who move from the clinical trial over to the commercial product, does paying for the therapy count as part of making sure treatment continues without interruption? I'm just trying to work out how many of those 242 scripts belong to patients coming off the trial, and how that number could turn into revenue both this quarter and later on. Then, on the sickle sNDA, I'm wondering when you expect the regulator to come back with feedback on the design you've proposed for the confirmatory study, and whether you'll share that as an update, or whether the next thing we hear about the program is simply that the sNDA has been filed.
Brian Goff
executiveYes; and I believe Sarah can — we'll handle them one at a time, beginning with thalassemia, and perhaps just offer a comment on the open-label extension and the studies.
Sarah Gheuens
executiveRight. So Alec, patients are currently in open-label extensions within the thal clinical program. Those continue to run, and naturally they let us keep demonstrating that the effect is maintained in this population. Beyond that, the share of U.S. patients enrolled in those trials is modest, since this is a large global study. Turning to sickle cell disease, we're quite happy with how the engagements have moved forward and with their speed alongside the FDA, which naturally lets us refine the submission timeline further. As such, we've revised our guidance to say a filing would come in Q2. Regarding the clinical trial, additional specifics will be shared before it appears on clinicaltrials.gov. Also, as we've said, data will be presented at or around EHA, and those results did inform us in this trial. Let me step back for a moment and stress that, as mentioned in my prepared remarks, this trial is likewise structured so that we put operational feasibility and probability of success first. That will be where our attention goes with this.
Alec Stranahan
analystAll right. Perhaps I can ask a follow-up regarding that continuity of treatment component. Of those 242 scripts, I suppose, what number got recorded as revenue during the quarter? And also, how do you expect that to develop as payer access becomes available across the next several quarters?
Brian Goff
executiveCecilia, would you like to speak to those metrics?
Cecilia Jones
executiveRight, so like we mentioned, we separated out the U.S. and the ex-U.S. revenue lines. For the U.S. piece, the best frame is that our PKD guidance was roughly $45 million to $50 million on an annual basis, and the quarter came in consistent with that, with thalassemia making up the remainder. There's a delay between prescriptions and patients actually starting therapy, which is the point Tsveta was making. We've observed it moving somewhat quicker than our expectation, though ultimately we expect it to land in that 10- to 12-week window.
Emily Bodnar
analystTo begin with, regarding the talks you've been having with the FDA concerning the sNDA in sickle cell disease, should we also anticipate a REMS for sickle cell disease? Or does that apply just to thalassemia? Then I have a second question. Since Phase II results in sickle cell for tebapivat are anticipated later this year, could you perhaps share what you hope to observe compared with Phase II data from mitapivat and etavopivat, so we can feel confident about that best-in-class profile?
Brian Goff
executiveSo, Sarah, we'll begin with the ongoing encouraging dialogue with the FDA and the REMS question.
Sarah Gheuens
executiveSure, absolutely. And as you're aware, at this point we've got a choice in front of us, since PYRUKYND and AQVESME are both available. Each one comes with its own set of advantages and drawbacks. Regardless of which path we take, our teams are capable of carrying out either one. And when it comes to the Phase II data, this is a study designed to find the right dose. So naturally, we're seeking a dose from Phase II that we can advance, while at the same time we want to see how deep and how broad the hemoglobin response is.
Eric Schmidt
analystCongratulations on a fantastic launch. Perhaps regarding that 242 prescription figure for the first quarter, clearly that is a massive number. Tsveta, I believe you mentioned to us during February that as of January 31, you had 44 prescriptions; therefore it appears a fairly significant acceleration occurred across February and March. Could you possibly just verify if my calculation is right? And perhaps reconcile that with what you said about not projecting the present run rate into future periods, since if anything, it sounds as though you are on a speeding-up trajectory.
Tsveta Milanova
executiveIndeed, we are quite thrilled by the progress, Eric. Also, those 242 prescriptions written by REMS-certified physicians as of January 31st capture the entire first quarter. Just to remind everyone, we actually began actively promoting this drug once we received the label. Thus demand was created across the entire quarter. The REMS went live at the close of January, yet demand was also created throughout January. So I view the quarter in its entirety. That is what I stated: I would not take these two figures and sort of extrapolate them into upcoming quarters, and I would not adopt that run rate. However, we continue to anticipate robust demand going forward, since the team is executing and both patients and physicians respond very favorably to the profile and wish to engage more.
Brian Goff
executiveEric, let me use this moment to build on what you said and emphasize that the AQVESME launch has something remarkable going for it, thanks to 3 key ingredients. To start, AQVESME tackles a substantial unmet need in thalassemia. Next, the community — meaning both physicians and patients — is already showing enthusiasm for the profile. And like you mentioned, third, Tsveta and the Agios team are extremely well prepared, they understand how to execute, and their early progress makes us very proud.
Eric Schmidt
analystThat's genuinely impressive movement. Can we get any clarity on the proportion of those first REMS-prescribing individuals who will probably switch over, or what that conversion rate looks like?
Tsveta Milanova
executiveDuring that opening quarter, like I said, we ended up really drawing in a group of patients who were among the most driven and involved, and the rate at which prescriptions turned into treatment starts actually moved more quickly than we had anticipated. As we move through subsequent quarters, our expectation remains that initiations will take 10 to 12 weeks consistently. We're going to attempt to bring that down; however, the main thing pushing that timeline is that we'll be entering patient groups whose contact with the health care system happens less often as we continue further into the NTDT segment, which we've discussed previously.
Eric Schmidt
analystEric, let me try putting that question another way: among those 242 patients who you currently believe are no longer probable to convert, have any been lost? Brian, your response?
Brian Goff
executiveTo this point, Eric, I'd describe the situation as one where the REMS has gained strong acceptance from physicians and, as Tsveta mentioned, from patients who are motivated; and regarding that early group who either began on AQVESME or received a prescription for it and afterward moved onto therapy, we have considerable confidence in what I'd term the elevated conversion rate.
Tsveta Milanova
executiveYeah. My apologies, Eric — perhaps I misunderstood what you were asking. The REMS doesn't stand in the way of starting treatment whatsoever. As for the conversion rate we're observing, that pattern is quite standard when a rare disease therapy launches. So the REMS isn't making our situation unusual.
Marc Frahm
analystCongratulations on how things are going with AQVESME. I want to pick up where some of the replies to Eric's questions left off. It sounds like at least a portion of those — the roughly 200 additional scripts you're referring to now, compared with the end of January — may actually have been written before January. Is that accurate? They simply hadn't come from a physician certified under the REMS, and essentially what has shifted is the certification status within the REMS. Is that the proper way to reconcile what's been said? And regarding the bit of caution about TRx trajectory perhaps decelerating, or fill time stretching out somewhat — have you truly observed that as of yet? Or are you merely being careful that it could occur as we head into upcoming quarters?
Brian Goff
executiveThanks, Marc. Perhaps the useful thing here is for me to back up a bit and go over the launch timeline and what happened during the first quarter, since demand got initiated and then the REMS got operationalized. Would you like to walk through that, and then speak to where the 242 prescriptions came from?
Tsveta Milanova
executiveAbsolutely. The 242 prescriptions reflect everything accomplished through strong launch preparation. We understood with considerable clarity where prescriptions would likely appear initially, and we began those interactions along with promotional efforts the moment the label arrived; thus, they represent our efforts across the entire quarter. During month one, our REMS was not yet functioning, and the team nonetheless performed outstandingly to secure prescriptions from physicians certified under REMS throughout that launch stage. Once REMS became operational, we carried on along that path. Naturally, additional physicians who had been awaiting that operational date before writing prescriptions then began doing so. We feel quite pleased by what we observe currently, since prescriptions are arriving with a very robust geographic spread. They originate from community prescribers, among whom most patients receive care at present. We also notice highly driven and involved patients beginning treatment, which is wonderful for us, given that we recognize the thalassemia community is in fact quite tightly interconnected and that this early launch experience among patients will in turn bolster favorable feedback as well as the product's profile. Therefore, what I can share is that going forward, I would not take those 2 data points from Q1 and extrapolate from them, yet I hold strong confidence that we will see robust uptake and penetration ahead as the launch proceeds, consistent with what is typical for non-life-threatening rare disease conditions.
Brian Goff
executiveMarc, regarding the latter portion of what you asked — those 10 to 12 weeks Tsveta mentioned during her prepared remarks — it's been encouraging to see that in certain instances, these motivated patients have moved onto therapy more quickly than that. That said, it still comes down to how motivated the physician is and how motivated the patient is. And the rationale for guiding toward an average — that's what we'd expect moving forward — is that as we go deeper into the non-transfusion-dependent patient population, we anticipate there may be something of a dampening effect when it comes to enthusiasm, and converting those patients to therapy could take somewhat longer.
Marc Frahm
analystAll right. That makes total sense, though let me probe a bit further — presumably, as the launch moves along, you'd also see a pattern where additional payers have their standard procedures in place, which typically compresses turnaround times with any particular payer. Yet from what I gather, you anticipate that this shift in excitement coming from the patients themselves will more than offset that.
Tsveta Milanova
executiveCorrect. Without a doubt — our team is performing extremely well at the moment, and no obstacles from payers have come up yet. Naturally, we'll keep seeking methods to cut down the interval between prescriptions being written and treatment getting started. We'll aim to make progress. Putting payer policies into effect generally requires roughly 6 months. Still, at this point, just like patients and physicians, payers have responded very favorably to the profile, and market access hasn't posed any barrier.
Lydia Erdman
analystLydia here, filling in for Salveen. Nice work on the launch updates. Perhaps one more thing about the launch. Could you describe the treating physicians and the treatment settings you're observing? Also, do most prescriptions still come from community hem-oncs? And has the team begun reaching out to doctors past those who were targeted before launch?
Tsveta Milanova
executiveYes, definitely; from a prescriber standpoint, the launch has gotten off to a very healthy start. Prescriptions have been arriving from both academic and community settings, yet most of them originate in the community, which matches precisely what we anticipated. That reflects how thalassemia patients are primarily managed within the community. Prescriptions are arriving from all over the country, which is wonderful; going forward, patients will keep expanding how broadly prescribing occurs; naturally, we'll concentrate on that too, but most of the business will keep growing breadth.
Tessa Romero
analystI'd like to go back to one of the first questions asked on this call. In the end, what implications do you see Novo's latest results having for what Agios does next? And how does that shift your thinking about what has to be shown to move tebapivat ahead in sickle cell disease too?
Brian Goff
executivePerhaps Sarah could begin with where we're focused on mitapivat, and after that we can say something about tebapivat too.
Sarah Gheuens
executiveAlright, the complete HIBISCUS data set isn't available to us at this point. Therefore, as Tsveta pointed out, we clearly perceive a commercial opening in sickle cell disease for mitapivat; and she also noted that because of how common this condition is and how devastating it can be, several companies are involved. Naturally, we intend to make the most of the commercial potential for mitapivat. Our RISE UP data sets make that achievable; once again, we have a notably potent antihemolytic profile in that data. The evidence for hemoglobin response is unquestionably solid, since, as we have emphasized, we have observed an effect on VOCs — yet sickle cell disease involves more than just VOCs; we have also observed effects on hospitalizations, fatigue, and quality of life. So there is genuinely considerable enthusiasm for our drug among patients and physicians in the community. And naturally, we are also — as we noted during our prepared remarks — quite happy with how our interactions with the FDA have advanced, which means we can now revise our anticipated filing to Q2. So we are quite happy with our current position.
Tessa Romero
analystAll right, that's helpful. Sarah, may I ask one quick thing that builds on what you just said? Once the complete HIBISCUS data set becomes available to us, is there any aspect you'd be eager to get a clearer picture of?
Sarah Gheuens
executiveYes, certainly — as things stand, the information we can currently access is quite scarce. So whatever concerns the usual measures used in a study, that's something I'd be very glad to review.
Gregory Renza
analystThis is < > calling in for Greg. Congratulations on the launch, Tsveta. I've got one question about AQVESME. With momentum that keeps growing, you had 242 prescriptions during the first quarter. Given that this is a chronic setting, are you beginning to observe any early indications of patient persistence, meaning patients remaining on therapy? And are there any variations in the patterns when comparing transfusion-dependent with non-transfusion dependent? And I have a follow-up.
Tsveta Milanova
executiveOf course. Like we mentioned, we're at a very early stage of the launch, and there's a delay between when a prescription is written and when treatment begins, and then patients have to get through a month of therapy before we can start to see what the continuation rate looks like; however, we've observed PYRUKYND in PK deficiency doing extremely well in the real world. We anticipate seeing that same strong performance in thalassemia too. At times we describe the REMS as sort of paperwork and work, but in fact, it assists with the frequent interactions between patients and physicians and in fact can help support continuation of therapy too. So we'll wait and see. That's one very important factor we'll keep monitoring.
Analyst
analystUnderstood — and then a follow-up regarding mitapivat in sickle cell disease. If we work from the assumption of accelerated approval, how are you viewing the chance for early adoption when hemoglobin serves as a surrogate endpoint and possibly appears on the label, while more outcomes data are still being produced in the confirmatory trial, and particularly given that etavopivat reached the VOC endpoint?
Brian Goff
executiveYes. This reflects somewhat what Sarah mentioned too — sickle cell disease carries an extremely high unmet need. And, as Sarah noted, it is a disease with multiple dimensions. Clinically, there are numerous aspects of sickle cell disease to tackle. With the RISE UP data we have observed, including the responder analysis, we feel proud and confident; and Tsveta, along with her team, is naturally already getting ready on the commercial side for that possible opportunity ahead through the accelerated approval pathway.
Sarah Gheuens
executiveIf I could just jump in here as well, the information coming out of RISE UP, which we've been bringing to the attention of doctors and patient groups, has gotten a really positive response.
Analyst
analystAnd if I could just ask, perhaps you could say a bit more about the confirmatory study? What's your thinking regarding the confirmatory endpoint? And in terms of treatment selection, how would that stack up against the potential VOC data we may observe in HIBISCUS?
Sarah Gheuens
executiveYeah. Thank you. So as was emphasized, the endpoint draws on the RISE UP data set, where we gathered information prospectively and systematically; we've also had excellent interactions with the FDA, and that's moved forward quite well. So once more, we can now discuss our plan to file in the second quarter. We've said before as well that we'll be presenting data at or near EHA covering all of the data, which includes the data behind this confirmatory trial, and we'll also share more prior to our posting on clinicaltrials.gov. The final point I'd like to emphasize, and it truly matters, is that this is a confirmatory trial. So we've genuinely made operational feasibility a priority, along with probability of success, so we can deliver meaningful data that would then, of course, let us at that point hopefully get that data into the label at the time of full approval, should the results permit. So we're extremely enthusiastic about where we stand right now; we have tremendous confidence in our data and in the path we're taking.
Brian Goff
executiveOkay, many thanks, Victor. And thank you to all of you for being here. Our first quarter obviously showed strong execution on the strategic priorities we've laid out — starting with the early momentum from AQVESME's U.S. commercial launch in thalassemia, which we've already talked about, then the ongoing work toward filing the mitapivat sNDA in sickle cell disease, and also keeping a disciplined approach on the financial side, with several significant catalysts still coming during this year. We feel Agios is in a good position as we head through 2026, and we're eager to keep sharing updates on how things are going, including at the investor event we have planned around the 2026 EHA Congress. So, thank you all very much.
Operator
operatorWe appreciate everyone joining us for this call. That brings the program to an end. You're welcome to log off now. Have a wonderful day, everybody.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Agios Pharmaceuticals, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Agios Pharmaceuticals, Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Agios Pharmaceuticals, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.